Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice

Journal of Infectious Diseases

Volumn 188, Issue 1, 2003, Pages 5-12

  Ben Nathan, David ^a   Lustig, Shlomo ^a   Tam, Guy ^b   Robinzon, Shahar ^b   Segal, Shraga ^b   Rager Zisman, Bracha ^b  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HUMAN IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; BLOOD DONOR; CELL PROTECTION; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; DRUG EFFICACY; ENCEPHALITIS; FEMALE; ISRAEL; MENINGITIS; NONHUMAN; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROPHYLAXIS; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICE, INBRED BALB C; TIME FACTORS; VIRUS REPLICATION; WEST NILE FEVER; WEST NILE VIRUS;

EID: 0038448987     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/376870     Document Type: Article

References (54)

1. Lanciotti RS, Roehrig JT, Deubel V, et al. Origin of West Nile virus responsible for an outbreaks of encephalitis in the northeastern United States. Science 1999; 286:2333-7.
2. Burke SD, Monath TP. Flaviviruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. Vol 1. 4th ed. Philadelphia: Lippincott-Raven, 2001:1043-125.
3. Hayes GC. West Nile fever. In: Monath TP, ed. The arboviruses: epidemiology and ecology. Vol 5. Boca Raton, FL: CRC Press, 1989:59-88.
4. Smithburn KC, Hughes TP, Burke AW, Paul JH. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med 1940; 20:471-92.
5. Briese T, Rambaut A, Pathmajeyan M, et al. Phylogenetic analysis of a human isolate from the 2000 Israel West Nile virus epidemic. Emerg Infect Dis 2002; 8:528-31.
6. Swayne DE, Beck JR, Smith CS, Shieh WJ, Zaki SR. Fatal encephalitis and myocarditis in young domestic geese (Anser anser domesticus) caused by West Nile virus. Emerg Infect Dis 2001; 7:751-3.
7. Taylor RM, Work TH, Hurlbrit HS, Rizk F. A study of the ecology of West Nile virus in Egypt. Am J Trop Med Hyg 1956; 5:579-620.
8. Akov Y, Goldwasser R. Prevalence of antibodies to arboviruses in various animals in Israel. Bull World Health Organ 1966; 34:901-9.
9. Cohn D, Zaide Y, Karasenty E, et al. Prevalence of antibodies to West Nile fever, sandfly fever Sicilian, and sandfly fever Naples viruses in healthy adults in Israel. Public Health Rev 1999; 27:217-30.
10. Goldblum N, Strek W, Padersky B. West Nile fever: the clinical features of the disease and isolation of West Nile from the blood of nine human cases. Am J Hyg 1954; 59:89-103.
11. Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI. West Nile encephalitis epidemic in southeastern Romania. Lancet 1998; 352:767-71.
12. Asnis DS, Conetta R, Teixeira AA, Waldman G, Sampson BA. The West Nile virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis 2000; 30:413-8.
13. Lanciotti RS, Ebel GD, Deubel V, et al. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 2002; 298:96-105.
14. Durand B, Chevalier V, Pouillot R, et al. West Nile virus outbreak in horses. Southern France, 2000: results of a serosurvey. Emerg Infect Dis 2002; 8:777-82.
15. Hubalek Z, Halouzka J. West Nile fever: a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis 1999; 5:643-50.
16. Autorino GL, Battish A, Deubel V, et al. West Nile virus epidemic in horses, Tuscany region, Italy. Emerg Infect Dis 2002; 8:1372-8.
17. Rappole JH, Derrickson SR, Hubalek Z. Migratory birds and spread of West Nile virus in the western hemisphere. Emerg Infect Dis 2000; 6:319-28.
18. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis 2002; 2:519-29.
19. L'Vov DK, Butenko AM, Gromanesky VL, et al. Isolation of two strains of West Nile virus during an outbreak in Southern Russia 1999. Emerg Infect Dis 2000; 6:373-6.
20. Weinberger M, Pitlik SD, Gandacu D, et al. West Nile fever outbreak, Israel, 2000: epidemiological aspects. Emerg Infect Dis 2001; 7:686-91.
21. Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel 2000. Emerg Infect Dis 2001; 7:675-8.
22. Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 1988; 141:3606-10.
23. Roehrig JT, Staudinger LA, Hunt AR, Mathews JH, Blair CD. Antibody prophylaxis and therapy for flavivirus encephalitis infections. In: White DJ, Morse DL, eds. West Nile virus detection, surveillance and control. Ann NY Acad Sci 2001; 951:286-97.
24. Broom AK, Wallace MJ, Mackenzie JS, Smith DW, Hall RA. Immunisation with gamma globulin to Murray Valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against Australian encephalitis: evaluation in a mouse model. J Med Virol 2000; 61:259-65.
25. Mathews JH, Roehrig JT. Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J Immunol 1984; 132:1533-7.
26. Phillotts RJ, Stephenson JR, Porterfield JS. Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus: brief report. Arch Virol 1987; 93:295-301.
27. Schlesinger JJ, Brandriss MW, Walsh EE. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J Immunol 1985; 135:2805-9.
28. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 2002; 8:833-41.
29. Casadevall A, Scharff MD. "Serum therapy" revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994; 38:1695-702.
30. Sonna PP, Burton DR. Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts. J Virol 2000; 74:9813-7.
31. Lustig S, Danenberg DH, Kafri Y, Kobiler D, Ben-Nathan D. Viral neuroinvasion and encephalitis induced by lipopolysaccharide and its mediators. J Exp Med 1992; 176:707-12.
32. Ben-Nathan D, Huitinga I, Lustig S, van Rooijen N, Kobiler D. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch Virol 1996; 141:459-69.
33. Lustig S, Olshevsky U, Ben-Nathan D, et al. A live attenuated West Nile virus strain as a potential veterinary vaccine. Viral Immunol 2000; 13:401-10.
34. Vaheri A, Sedwick WD, Plotkin S, Maes AR. Cytopathic effect of rubella virus in BHK-21 cells and growth of high titers in suspension cultures. Virology 1965; 27:239-41.
35. Jia XY, Briese T, Jordan I, et al. Genetic analysis of West Nile New York 1999 encephalitis virus. Lancet 1999; 354:1971-2.
36. Ben-Nathan D, Lachmi B, Lustig S, Feuerstein G. Protection of dehydroepiandrosterone (DHEA) in mice infected with viral encephalitis. Arch Virol 1991; 120:263-71.
37. Reed LJ, Muench H. A simple method of estimating fifty percent end points. Am J Hyg 1938; 27:493-7.
38. Mahy BWJ, Kangro HO. Whole cell antigen preparations. In: Virology methods manual. London: Academic Press, 1996:49-53.
39. Feinstein S, Akov Y, Lachmi B, Lehrer S, Rannon L, Katz D. Determination of human IgG and IgM class antibodies to West Nile virus by enzyme linked immunosorbent assay (ELISA). J Med Virol 1985; 17:63-72.
40. Martin DA, Muth DA, Brown D, Johnson AJ, Karabatsos N, Roehrig JT. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 2000; 38:1823-6.
41. Diamond MS, Shreshha B, Marri A, Mahan D, Engle M. B cell and antibody play a critical role in the defense of disseminated infection by West Nile encephalitis virus. J Virol 2003; 77:2578-86.
42. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol 2001; 75:4649-54.
43. Roehrig JT, Hunt AR, Kinney RM, Mathews JH. In vitro mechanism of monoclonal antibody neutralization of alphaviruses. Virology 1988; 165:66-73.
44. Kreil TR, Eibl MM. Pre and postexposure protection by passive immunoglobulin, but no enhancement of infection with a flavivirus in a mouse model. J Virol 1997; 71:2921-7.
45. Griffin D, Levine B, Tyor W, Ubol S, Despres P. The role of antibody in recovery from alphavirus encephalitis. Immunol Rev 1997; 159:155-61.
46. Levine B, Hardwick JM, Trapp BD, Crawford TO, Bollinger RC, Griffin DE. Antibody-mediated clearance of alphavirus infection from neurons. Science 1991; 254:856-60.
47. Schneider-Schaulies S, Liebert UG, Segev Y, Rager- Zisman B, Wolfson M, ter Meulen V. Antibody-dependent transcriptional regulation of measles virus in persistently infected neuronal cells. J Virol 1992; 66:5534-41.
48. Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralizing antibodies in treatment of Argentine haemorrhagic fever with immune serum. Lancet 1984; 2:255-6.
49. Huang YC, Lin TY, Lin YJ, Lien RI, Chou YH. Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella. Eur J Pediatr 2001; 160:91-4.
50. Geller TJ, Condie D. A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J Neurol Sci 1995; 129:131-3.
51. Selbing A, Josefsson A, Dahle LO, Lindgren R. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet 1995; 11:660-1.
52. Andersen JB, Rasmussen LH, Herning M, et al. Dramatic improvement of severe acute disseminated encephalomyelitis after treatment with intravenous immunoglobulin in a three-year-old boy. Dev Med Child Neurol 2001; 43:136-8.
53. Shimoni Z, Niven M, Pitlik S, Bulrik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001; 7:759.
54. Hamdan A, Green P, Mendelson E, Kramer MR, Pitlik S, Weinberger M. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transp Infect Dis 2002; 4:160-2.